Reading view
Sequencing-free whole-genome spatial transcriptomics at single-molecule resolution
Fifteen challenges for generative AI applications to cell biology
Occamy-1.0: Open Pareto-frontier 35B Intelligence for Co-work
Toward Robust Personalized Alignment for LLMs: Mitigating Persona Drift in Multi-Turn Dialogue
BlueLM-GUI Technical Report: A Real-Device-Centric Flywheel for Self-Improving Mobile GUI Agents
Beyond the Query: Do Retrieval Signals Improve Adaptive Multimodal RAG Routing?
Bridging the Gap in Ophthalmic AI: MM-Retinal-Reason Dataset and OphthaReason Model toward Dynamic Multimodal Reasoning
Hurdle-RMIL: Addressing Zero Inflation and Long-Tailed Imbalance in Infrared Rainfall Retrieval
VBVR-Pro: A Scalable and Verifiable Suite for Native Visual Reasoning
An engineered nanopore identifies saccharides, amino acids, peptides and ribonucleotides
Nature Biotechnology, Published online: 14 September 2026; doi:10.1038/s41587-026-03308-9
Modified nanopore simultaneously identifies diverse biomolecules and their modifications.Key Experimental Therapeutics and Knowledge Gaps in Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Drug Des Devel Ther. 2026 Sep 5;20:543657. doi: 10.2147/DDDT.S543657. eCollection 2026.
ABSTRACT
Metabolic dysfunction-associated steatohepatitis (MASH) is not solely a disorder of hepatocellular lipid accumulation, but a multicellular disease driven by coordinated metabolic stress, sterile inflammation, fibrogenesis, and niche remodeling. Recent therapeutic progress with the provisional approval of resmetirom and semaglutide has validated MASH as a tractable clinical target. However, many experimental agents have shown limited or inconsistent efficacy, particularly for regression of hepatic fibrosis or cirrhosis, reflecting the biological heterogeneity and dynamic cellular architecture of the disease. Distinct from conventional pathway- or drug class-based reviews, we summarize emerging therapeutics through a liver cell-centered framework, integrating hepatocyte-directed metabolic therapies, immune-cell modulation, hepatic stellate cell-targeted antifibrotic strategies, niche-directed approaches involving liver sinusoidal endothelial cells and cholangiocytes, systemic multi-cell modulators, and precision-delivery technologies. We further compare how these interventions reshape pathogenic communication among hepatic and extrahepatic compartments, while emphasizing unresolved challenges in drug target selection, cellular specificity, disease-stage dependency, safety, and patient stratification. This perspective emphasizes the need to move from isolated pathway targeting toward cell- and network-informed therapeutic strategies supported by spatial multi-omics, human-relevant models, and precision delivery.
PMID:42719321 | PMC:PMC13557022 | DOI:10.2147/DDDT.S543657
Impact of LLM-supported patient education on patient perspectives and patient-reported outcomes: a mixed-methods systematic review
npj Digital Medicine, Published online: 10 September 2026; doi:10.1038/s41746-026-03228-7
Impact of LLM-supported patient education on patient perspectives and patient-reported outcomes: a mixed-methods systematic review